OrthoPediatrics Corp. (NASDAQ:KIDS – Get Rating) EVP Gregory A. Odle sold 1,771 shares of the stock in a transaction on Friday, January 13th. The stock was sold at an average price of $45.00, for a total value of $79,695.00. Following the transaction, the executive vice president now directly owns 73,125 shares in the company, valued at approximately $3,290,625. The transaction was disclosed in a filing with the SEC, which is available at this link.
OrthoPediatrics Stock Performance
OrthoPediatrics stock opened at $44.15 on Wednesday. The stock has a 50-day moving average of $41.38 and a two-hundred day moving average of $45.18. OrthoPediatrics Corp. has a one year low of $35.67 and a one year high of $60.75. The stock has a market cap of $1.01 billion, a PE ratio of 116.18 and a beta of 0.80.
OrthoPediatrics (NASDAQ:KIDS – Get Rating) last released its quarterly earnings results on Monday, October 31st. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.14. OrthoPediatrics had a negative return on equity of 5.60% and a net margin of 7.90%. The company had revenue of $34.95 million during the quarter, compared to analysts’ expectations of $36.44 million. As a group, sell-side analysts predict that OrthoPediatrics Corp. will post -0.69 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on KIDS. Piper Sandler dropped their price target on OrthoPediatrics from $58.00 to $52.00 in a research report on Tuesday, November 1st. Stifel Nicolaus dropped their price objective on OrthoPediatrics from $52.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, January 10th. TheStreet raised OrthoPediatrics from a “d+” rating to a “c” rating in a research report on Tuesday, November 1st. JMP Securities dropped their price objective on OrthoPediatrics from $70.00 to $60.00 and set a “market outperform” rating on the stock in a research report on Wednesday, November 2nd. Finally, Needham & Company LLC dropped their price objective on OrthoPediatrics from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, November 1st. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $54.33.
OrthoPediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
- Get a free copy of the StockNews.com research report on OrthoPediatrics (KIDS)
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
- Tritium Is the Largest DC EV Charger Maker You’ve Never Heard Of
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.